WVE
Wave Life Sciences, Inc.Company Information
- Company Name
- Wave Life Sciences, Inc.
- CIK
- CIK0001631574
- Category
- Large accelerated filer
- Ticker: Exchange
- WVE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- WVE
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-30
- Last sale
- 2026-08-12
- Shares purchased (TTM)
- 2,442,091
- Shares sold (TTM)
- 1,170,725
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 180,877,169
- Shares outstanding
- 204,008,712
- Ownership
- 88.66%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 368 | 545 | 602 | 196 | 208 | 243 | 302 | 311 | 154 | 181 | 200 | 140 | ||||||
| Marketable Securities | 123 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 1 | 0 | 1 | 10 | 2 | - | 1 | 0 | 1 | 0 | 21 | 7 | ||||||
| Prepaid Expense Current | 12 | 13 | 8 | 7 | 7 | 8 | 10 | 11 | 12 | 11 | 10 | 8 | ||||||
| Other Assets Current | 4 | 3 | 3 | 3 | 7 | 7 | 7 | 3 | 5 | 5 | 4 | 4 | ||||||
| Assets Current | 508 | 561 | 615 | 215 | 224 | 258 | 320 | 325 | 172 | 197 | 235 | 159 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 7 | 7 | 7 | 8 | 9 | 10 | 10 | 11 | 12 | 12 | 13 | 14 | ||||||
| Operating Lease Right Of Use Asset | 39 | 11 | 12 | 14 | 15 | 17 | 18 | 19 | 20 | 22 | 23 | 24 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Other Assets | - | - | - | - | - | - | - | 0 | 1 | 1 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 0 | 0 | 0 | 1 | 0 | 0 | - | - | - | 0 | - | ||||||
| Assets Noncurrent | 51 | 22 | 24 | 26 | 29 | 30 | 32 | 34 | 37 | 39 | 40 | 41 | ||||||
| Assets | 558 | 584 | 638 | 241 | 252 | 288 | 352 | 359 | 209 | 235 | 275 | 200 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 20 | 19 | 16 | 14 | 15 | 14 | 16 | 13 | 18 | 12 | 13 | 13 | ||||||
| Accrued Liabilities And Other Liabilities | 18 | 13 | 27 | 16 | 13 | 8 | 21 | 15 | 11 | 7 | 17 | 13 | ||||||
| Contract With Customer Liability Current | 9 | 9 | 44 | 47 | 52 | 57 | 66 | 136 | 137 | 141 | 150 | 68 | ||||||
| Operating Lease Liability Current | 4 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | ||||||
| Liabilities Current | 51 | 50 | 95 | 86 | 87 | 87 | 111 | 171 | 173 | 166 | 186 | 100 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | 14 | 15 | 8 | 12 | 4 | 6 | 6 | 18 | 10 | 13 | 16 | 105 | ||||||
| Operating Lease Liability Noncurrent | 40 | 7 | 9 | 11 | 14 | 16 | 18 | 20 | 22 | 24 | 25 | 27 | ||||||
| Liabilities Noncurrent | 54 | 22 | 17 | 23 | 18 | 21 | 24 | 38 | 31 | 36 | 41 | 133 | ||||||
| Liabilities | 105 | 72 | 112 | 109 | 105 | 109 | 135 | 209 | 204 | 202 | 227 | 233 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 0 | 0 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1,627 | 1,627 | 1,616 | 1,224 | 1,191 | 1,179 | 1,175 | 1,140 | 951 | 950 | 935 | 841 | ||||||
| Additional Paid In Capital | 248 | 237 | 228 | 174 | 168 | 161 | 156 | 153 | 136 | 132 | 129 | 127 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,422 | -1,352 | -1,326 | -1,273 | -1,219 | -1,169 | -1,122 | -1,151 | -1,089 | -1,056 | -1,025 | -1,009 | ||||||
| Stockholders Equity | 454 | 512 | 518 | 125 | 139 | 172 | 210 | 142 | -3 | 25 | 40 | -40 | ||||||
| Liabilities And Stockholders Equity | 558 | 584 | 638 | 241 | 252 | 288 | 352 | 359 | 209 | 235 | 275 | 200 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 51 | 50 | 50 | 49 | 48 | 47 | 46 | 45 | 44 | 44 | 43 | 42 | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Issued | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 193 | 192 | 188 | 160 | 156 | 154 | 153 | 148 | 122 | 122 | 119 | 99 | ||||||
| Shares Outstanding | 193 | 192 | 188 | 160 | 156 | 154 | 153 | 148 | 122 | 122 | 119 | 99 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialWave Life Sciences, Inc. (WVE) — SEC Financial Statements & Analysis
Wave Life Sciences, Inc. (WVE) is a pharmaceutical preparations company, incorporated in DE. Wave Life Sciences, Inc. trades on Nasdaq as: WVE. Wave Life Sciences, Inc. (WVE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, Wave Life Sciences, Inc. carries a market cap of $1.19B, a P/E ratio of -5.85x, a P/B ratio of 2.61x, a P/S ratio of 29.25x, an enterprise value of $817.28M, and an EV/EBITDA multiple of -3.81x. On profitability, it posts an operating margin of -537.84%, a net margin of -499.71%, a Return on Equity (ROE) of -68.31%, a Return on Assets (ROA) of -49.95%, and a Return on Invested Capital (ROIC) of -2495.53%. Per share, it reports EPS of $-0.99, diluted EPS of $-0.99, free cash flow per share of $-0.95, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 126.69% year-over-year, net income growth of 55.90% year-over-year, and EPS growth of 25.32% year-over-year. On the balance sheet, it maintains a current ratio of 9.99x, a quick ratio of 9.75x, working capital of $456.69M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.19, free cash flow of $-193.15M (TTM), and net debt of $-368.01M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.19B
- P/E TTM
- -5.85x
- EPS TTM
- $-0.99
- P/B TTM
- 2.61x
- ROE TTM
- -68.31%
- ROA TTM
- -49.95%
- Debt To Equity
- 0.23x
- Free Cash Flow TTM
- $-193.15M
- Net Revenue TTM Growth 1Y
- 126.69%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Wave Life Sciences, Inc. in?
Wave Life Sciences, Inc. (WVE) operates in the Pharmaceutical Preparations industry.
What exchange does WVE trade on?
Wave Life Sciences, Inc. (WVE) trades on the Nasdaq.
Where is Wave Life Sciences, Inc. incorporated?
Wave Life Sciences, Inc. is incorporated in DE.
When was Wave Life Sciences, Inc. (WVE)'s most recent SEC filing?
Wave Life Sciences, Inc. (WVE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is WVE's market cap?
Wave Life Sciences, Inc. (WVE) has a market capitalization of $1.19B as of 2026-06-30.
What is WVE's EPS (earnings per share)?
Wave Life Sciences, Inc. (WVE)'s trailing twelve month EPS is $-0.99 as of 2026-06-30.
What is WVE's ROE (return on equity)?
Wave Life Sciences, Inc. (WVE)'s trailing twelve month Return on Equity (ROE) is -68.31% as of 2026-06-30.
What is WVE's ROA (return on assets)?
Wave Life Sciences, Inc. (WVE)'s trailing twelve month Return on Assets (ROA) is -49.95% as of 2026-06-30.
What is WVE's ROIC (return on invested capital)?
Wave Life Sciences, Inc. (WVE)'s trailing twelve month Return on Invested Capital (ROIC) is -2495.53% as of 2026-06-30.
What is WVE's EV/EBITDA?
Wave Life Sciences, Inc. (WVE)'s trailing twelve month EV/EBITDA is -3.81x as of 2026-06-30.